Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

PharmaMar S.A.. (11/16/16). "Press Release: PharmaMar Appoints Pascal Besman as Chief Operating Officer of PharmaMar U.S.". Madrid & New York, NY.

Organisations Organisation PharmaMar (US)
  Group PharmaMar (Group)
  Organisation 2 Maxim Group LLC
Products Product Yondelis®
  Product 2 investment banking
Persons Person Besman, Pascal (PharmaMar 201611– COO of PharmaMar US before Maxim Group + JMP Securities + UBS + Bear Stearns)
  Person 2 Fernandéz Sousa-Faro, José María (Zeltia 201411 Chairman of Zeltia + PharmaMar)
     


Newly-Created Executive Role to Support Company’s Planned Expansion of U.S. Operations


PharmaMar (MSE:PHM), a biotechnology company developing marine-derived oncology drugs, today announced that Pascal Besman has joined the company in the newly-created role of Chief Operating Officer, effective immediately. Mr. Besman will be based in New York and will oversee the implementation of PharmaMar’s operational infrastructure in the United States. Mr. Besman joins PharmaMar from Maxim Group, a New York-based global investment bank, where he served as Head of Healthcare Equity Sales since 2014.

“With Yondelis on the market in the US and our key pipeline program PM1183 in several pivotal Phase 3 studies, now is the ideal time to welcome Pascal to our team as we further expand our presence in the U.S.,” said José María Fernández Sousa-Faro, Ph.D., President, Chief Executive Officer and Chairman of the Board of PharmaMar. “As a global, revenue-generating oncology company, we look forward to leveraging Pascal’s expertise in the biotechnology sector and U.S. capital markets as we continue to expand our efforts in the US.”

“I have been impressed with PharmaMar’s progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines,” said Mr. Besman. “PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company’s future success as we seek to continue building shareholder value.”

In addition to Maxim Group, Mr. Besman served as a healthcare specialist and institutional equity salesperson at several investment banks, including JMP Securities, UBS, Bear Stearns, Lehman Brothers and Merrill Lynch. He authored a widely-read weekly biotech overview newsletter for C-suite executives entitled The Buzz. Mr. Besman holds a B.Sc. from the London School of Economics.


About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.


Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.


Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com

   
Record changed: 2016-12-05

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for PharmaMar (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 120x180px Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 120x180px